QualityStocksNewsBreaks – InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) Teams with Pharmaseed to Advance Development of INM-750
Preclinical stage biopharmaceutical company InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) this morning announced its entry into an agreement with Pharmaseed Ltd., Israel’s largest GLP-certified pre-clinical contract research organization. Under the terms of this agreement, the Pharmaseed development team will now play a key role in the ongoing development of InMed’s lead compound, INM-750, which is a proprietary, topical cannabinoid product candidate that’s currently being studied as a therapy in epidermolysis bullosa and other potential dermatological and wound-healing applications. “This agreement with Pharmaseed now adds one of Israel's leading formulation development teams to our efforts and represents an important strategic…